Neuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence
The DOI matches its Crossref record; 240 of the 241 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Knowledge of the neural mechanisms underlying the development of benzodiazepine (BZ) dependence remains incomplete. The gamma-aminobutyric acid (GABA(A)) receptor, being the main locus of BZ action, has been the main focus to date in studies performed to elucidate the neuroadaptive processes underlying BZ tolerance and withdrawal in preclinical studies. Despite this intensive effort, however, no clear consensus has been reached on the exact contribution of neuroadaptive processes at the level of the GABA(A) receptor to the development of BZ tolerance and withdrawal. It is likely that changes at the level of this receptor are inadequate in themselves as an explanation of these neuroadaptive processes and that neuroadaptations in other receptor systems are important in the development of BZ dependence. In particular, it has been hypothesised that as part of compensatory mechanisms to diazepam-induced chronic enhancement of GABAergic inhibition, excitatory mechanisms (including the glutamatergic system) become more sensitive [Behav. Pharmacol. 6 (1995) 425], conceivably contributing to BZ tolerance development and/or expression of withdrawal symptoms on cessation of treatment, including increased anxiety and seizure activity. Glutamate is a key candidate for changes in excitatory transmission mechanisms and BZ dependence, (1) since there are defined neuroanatomical relationships between glutamatergic and GABAergic neurons in the CNS and (2) because of the pivotal role of glutamatergic neurotransmission in mediating many forms of synaptic plasticity in the CNS, such as long-term potentiation and kindling events. Thus, it is highly possible that glutamatergic processes are also involved in the neuroadaptive processes in drug dependence, which can conceivably be considered as a form of synaptic plasticity. This review provides an overview of studies investigating changes in the GABAergic and glutamatergic systems in the brain associated with BZ dependence, with particular attention to the possible differential involvement of N-methyl-D-aspartate and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors in these processes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Regular use of BZDs has been shown to cause serious, harmful psychological and physical dependence, leading to withdrawal symptoms similar to that of alcohol withdrawal.”
From Benzodiazepines: Uses, Dangers, and Clinical Considerations (2021) · cites this paper as [52]
In the citing paper
“Psychological symptoms include increased excitability, nightmares, anxiety, insomnia, panic attacks, depression, hallucinations, irritability, paranoid thoughts, social phobia, poor memory, poor concentration, delirium, and even psychosis.”
From Benzodiazepines: Uses, Dangers, and Clinical Considerations (2021) · cites this paper as [52]
In the citing paper
“Withdrawal occurs as the BZD concentration in blood and tissue declines, generally causing symptoms opposite to that of the drug’s therapeutic effects.”
From Benzodiazepines: Uses, Dangers, and Clinical Considerations (2021) · cites this paper as [52]
In the citing paper
“Physical symptoms include headache, seizures, pain or stiffness in the head and neck region, an altered sensation of limbs, weakness and fatigue, tingling and numbness, muscle twitches, tremors, gastrointestinal symptoms (abdominal distension, nausea, diarrhea, constipation, etc.), appetite and weight changes, unusual smell, and others have been documented [52].”
From Benzodiazepines: Uses, Dangers, and Clinical Considerations (2021) · cites this paper as [52]
In the citing paper
“On the other hand, the excitatory glutamate system has also been implicated to play a role in the development of benzodiazepine tolerance [5].”
From Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective Receptor Modulators? (2012) · cites this paper as [5]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
A synaptic model of memory: long-term potentiation in the hippocampus
Bliss, T. V. P., & Collingridge, G. L. (1993) · Nature · doi:10.1038/361031a0 · Cited by 11,566
Bliss, T. V. P., & Gardner‐Medwin, A. R. (1973) · The Journal of Physiology · doi:10.1113/jphysiol.1973.sp010274 · Cited by 7,437
The neural basis of drug craving: An incentive-sensitization theory of addiction
Robinson, T. (1993) · Brain Research Reviews · doi:10.1016/0165-0173(93)90013-p · Cited by 7,346
Hollmann, M., & Heinemann, S. (1994) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.17.030194.000335 · Cited by 3,975
Monyer, H., Burnashev, N., Laurie, D. J., Sakmann, B., & Seeburg, P. H. (1994) · Neuron · doi:10.1016/0896-6273(94)90210-0 · Cited by 3,535
PHARMACOLOGY AND FUNCTIONS OF METABOTROPIC GLUTAMATE RECEPTORS
Conn, P. J., & Pin, J.-P. (1997) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.37.1.205 · Cited by 3,081
Psychopharmacology: The Fourth Generation of Progress
Bloom, F. E., & Kupfer, D. J. (1995) · Medical Entomology and Zoology · Cited by 2,985
Handbook of Psychopharmacology
(1988) · Springer eBooks · doi:10.1007/978-1-4613-0933-8 · Cited by 2,746
Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders
Epstein, F. H., Lipton, S. A., & Rosenberg, P. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300907 · Cited by 2,658
Choi, D. W. (1992) · Journal of Neurobiology · doi:10.1002/neu.480230915 · Cited by 2,314
Research works printed but not linked: 5
- Allison, 1999, Alterations in AMPA receptor binding during withdrawal sensitisation from benzodiazepines, Behav Pharmacol, 10, S2
- Jeevanjee, 1985, Is FG7142 mediated kindling due to changes in efficacy at the BZ/GABA receptor complex?, Br J Pharmacol, 84, 188P
- Roca, 1990, Chronic agonist exposure induces downregulation and allosteric uncoupling of the GABA/benzodiazepine receptor complex, Mol Pharmacol, 37, 37
- Sloan, 1991, Duration of diazepam (dz) treatment and the intensity of flumazenil precipitated abstinence (fpa) in dogs, FASEB J, 5, 703
- Zhao, 1994, Reduced expression of GABAA/benzodiazepine receptor γ2 and α5 subunit mRNAs in brain regions of flurazepam treated rats, Mol Pharmacol, 45, 657
Cited by
The neurobiology and control of anxious states
Millan, M. J. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00087-x · Cited by 965
The diagnosis and management of benzodiazepine dependence
Ashton, H. (2005) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000165594.60434.84 · Cited by 455
“Changes in the glutaminergic system may include sensitization of N-methyl-D-aspartate (NMDA) and possibly other receptors [1, 37 ].”
BackgroundBenzodiazepines: Uses, Dangers, and Clinical Considerations
Edinoff, A. N., Nix, C. A., Hollier, J., Sagrera, C. E., Delacroix, B. M., Abubakar, T., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2021) · Neurology International · doi:10.3390/neurolint13040059 · Cited by 340
“), appetite and weight changes, unusual smell, and others have been documented [52].”
BackgroundClassics in Chemical Neuroscience: Diazepam (Valium)
Calcaterra, N. E., & Barrow, J. C. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn5000056 · Cited by 281
Drugs as instruments: A new framework for non-addictive psychoactive drug use
Müller, C. P., & Schumann, G. (2011) · Behavioral and Brain Sciences · doi:10.1017/s0140525x11000057 · Cited by 286
Metadata
- Authors
- Allison, C., & Pratt, J. A.
- Affiliations
- University of Strathclyde (GB)
- Corresponding author
- Pratt, J.A
- ORCID
- Pratt, J.A
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2003-05
- Volume
- 98
- Issue
- 2
- Pages
- 171-195
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W1969765270
- Cited by
- 160
- References
- 241
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 7 · 2023: 6 · 2022: 4 · 2021: 10 · 2020: 12 · 2018: 9 · 2017: 2 · 2016: 7 · 2015: 5 · 2014: 7 · 2013: 10 · 2012: 9
- FWCI
- 0.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Pharmacology & Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Keywords
- benzodiazepine dependence, neural adaptation, GABAA receptor, glutamatergic system, NMDA receptor, AMPA receptors, drug tolerance, withdrawal, synaptic plasticity, diazepam, excitation-inhibition balance
- MeSH terms
- Benzodiazepines, Humans, Neuronal Plasticity, Receptors, GABA-A, Substance Withdrawal Syndrome, Synaptic Membranes, Anti-Anxiety Agents, Receptors, N-Methyl-D-Aspartate, Receptors, Glutamate, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence. https://app.cochat.ai/papers/10.1016/s0163-7258(03)00029-9
- The paper
- Allison, C., & Pratt, J. A. (2003). Neuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence. Pharmacology & Therapeutics. https://doi.org/10.1016/s0163-7258(03)00029-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.